Central Retinal Vein Occlusion Clinical Trial
Official title:
A Randomized, Double Masked, Multicenter, Phase II Study Assessing the Safety and Efficacy of 601 Versus Ranibizumab in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to macular edema secondary to CRVO
Following a 14-day maximum screening period, patients will be randomized and followed for approximately 52 weeks. Treatment visits will be scheduled in 4-week intervals. After 6 initial monthly injections of 601 or ranibizumab (loading phase), subjects will enter an individualized flexible treatment (IFT) phase (week 24 to week 48). During the IFT phase, an assessment of disease stability will be performed at each monthly visit and subjects will receive either an injection or not. Safety and efficacy outcomes will continue to be evaluated up to a period of 52 weeks unless the patient is withdrawn or discontinues the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
| Completed |
NCT01969708 -
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
|
Phase 3 | |
| Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
| Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
| Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
| Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
| Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
| Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
| Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
| Recruiting |
NCT04601701 -
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
| Withdrawn |
NCT03417401 -
Surgical Stabilizer Assisted RVC With rtPA for CRVO
|
Phase 1 | |
| Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
| Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
| Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
| Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
| Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
| Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
| Active, not recruiting |
NCT04793100 -
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
|
N/A | |
| Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 |